This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_VULVA_EXALLC for full statistics.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule
Sex
only females
239906
Check conditions
not C3_VULVA
239696
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D07.1&
Hospital discharge: ICD-9
2333B
Cause of death: ICD-10
D07.1&
Cause of death: ICD-9
2333B
Cancer registry: Topography ICD-O-3
C51
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
2
3 out of 7 registries used, show all original rules.
171
Check minimum number of events None
171
Include endpoints None
171
Remove individuals based on genotype QC
162
CD2_INSITU_VULVA
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Parent code in ICD-10
D07
Name in latin
Carcinoma in situ penis
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of vulva
based on the number of shared cases.
Broader endpoints:
- Carcinoma in situ of vulva (controls excluding all cancers)
- Carcinoma in situ of other and unspecified genital organs
- Carcinoma in situ of other and unspecified genital organs (controls excluding all cancers)
- In situ neoplasms (controls excluding all cancers)
- In situ neoplasms
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 162 | 162 | - |
| Unadjusted prevalence (%) | 0.04 | 0.07 | - |
| Mean age at first event (years) | 56.73 | 56.73 | - |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_VULVA – Carcinoma in situ of vulva
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Carcinoma in situ of vulva
↥Endpoint not on priority list, no data to show.